Notably, neoadjuvant therapy inhibited the proliferation of tumor cells in subcutaneous tumor as well as in metastatic foci, as demonstrated by significantly reduced Ki67 staining (Fig. 5f–h and S3). This evidence concerns the gene MKI67 and neoplasm.